Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07473128 · ClinicalTrials.gov registry record · Phase 3
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer
A Phase 3 study, sponsored by Pharmacosmos A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT07473128: Recruiting Phase 3 study, sponsored by Pharmacosmos A/S.
NCT07473128 is a Phase 3 study that is actively recruiting participants, run by Pharmacosmos A/S. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07473128, a Phase 3 study, is actively recruiting participants, sponsored by Pharmacosmos A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Primary Outcome
Duration and occurrence of severe neutropenia
Interventions
- DRUG Trilaciclib
- DRUG Saline (0.9% NaCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What NCT07473128 shows while recruiting
NCT07473128 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Trilaciclib is the first listed.
NCT07473128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07473128 about?
NCT07473128 is a clinical study titled "Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer". The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Pa...
What is the current status of trial NCT07473128?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2026-06-30. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07473128?
The interventions under investigation include: Trilaciclib (DRUG), Saline (0.9% NaCl) (DRUG).
Who is sponsoring clinical trial NCT07473128?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07473128's enrollment target sits among peer trials
120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI